Special Collection: Immunotherapy of Asthma and Traditional and novel immunotherapeutics and their mechanism of action in changing the allergic immune response Special Collection Editor: Associate Professor Menno van Zelm, Monash University, and The Alfred Hospital, , Description of Special Collection

Allergen desensitization for IgE-mediated allergic disease is the oldest form of immunotherapy. Despite being applied for over a hundred years with beneficial clinical outcomes, long-term outcomes typically require three or more years of treatment and there are still gaps in precision diagnostics for accurate identification of the relevant allergenic trigger.

We welcome original research, reviews, commentaries and TrialsWatch articles addressing a range of topics that contribute to our understanding of the immunotherapeutic treatment options for asthma and , including:

- Immunological mechanisms of allergen immunotherapy - Novel developments in peptide immunotherapy - Treatment intervention with novel biologicals - Treatment strategies that combine immunotherapy with microbiome manipulation and/or biologicals

We are also interested in articles summarising recent advances in the identification of new targets for the treatment of food and environmental allergies, including first-in-human studies and negative clinical trials where they provide a mechanistic insight.

Submission

Submissions for this series are welcome throughout 2021. For more information on submission, please contact our Editorial Office at journals@.org

When submitting your article as part of the series, please reference the series in your cover letter. Those interested in submitting a review or TrialsWatch article are encouraged to submit a short summary or proposal for consideration. Articles submitted to the series will be subject to our assessment by our Editorial team prior to peer review. Contributions to the series will be sent for external peer review as standard and acceptance is not guaranteed. Manuscripts which are out of scope for the collection, may still be considered for publication in the journal as part of a regular issue. Why submit?

Immunotherapy Advances offers authors:

• Rapid turnaround time

• High-quality peer review • Professionally produced graphical abstracts

• Dedicated collection promotion via Society and publisher

• BSI members receive a 20% discount on publication fees